ETCTN A phase 1 study of blinatumomab in combination with checkpoint inhibitor(s) of PD-1 (nivolumab) or both PD-1 (nivolumab) and CTLA-4 (ipilimumab) in patients with poor-risk; relapsed or refractory CD19+ precursor B-lymphoblastic leukemia Adult CIRB - Early Phase Emphasis Active Available to Open